Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 39 citing articles:

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 5, pp. 479-505
Open Access | Times Cited: 1427
MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone
Nicholas Russell, Mathis Grossmann
European Journal of Endocrinology (2019) Vol. 181, Iss. 1, pp. R23-R43
Open Access | Times Cited: 110
Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study
Suzanne K. Chambers, Melissa K. Hyde, Kirstyn Laurie, et al.
BMJ Open (2018) Vol. 8, Iss. 2, pp. e019917-e019917
Open Access | Times Cited: 64
Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management
Lisa M. Gudenkauf, S. Gray, Brian D. Gonzalez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7
Estrogen Receptors: Therapeutic Perspectives for the Treatment of Cardiac Dysfunction after Myocardial Infarction
Jaqueline da Silva, Tadeu L. Montagnoli, Bruna Rocha, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 525-525
Open Access | Times Cited: 39
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme
Ruth E. Langley, Duncan C. Gilbert, Trinh Duong, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 581-591
Open Access | Times Cited: 34
The loss of estradiol by androgen deprivation in prostate cancer patients shows the importance of estrogens in males
Herjan J.T. Coelingh Bennink, Amanda Prowse, Jan F M Egberts, et al.
Journal of the Endocrine Society (2024) Vol. 8, Iss. 7
Open Access | Times Cited: 5
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian Duchesne, Henry H. Woo, Madeleine King, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 9, pp. 1192-1201
Closed Access | Times Cited: 48
Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
Z.A. Siddiqui, Daniel Krauss
Translational Andrology and Urology (2018) Vol. 7, Iss. 3, pp. 378-389
Open Access | Times Cited: 34
Impact of prostate cancer treatments on men’s understanding of their masculinity.
Vivian W. L. Tsang, Charlenn Skead, Richard J. Wassersug, et al.
Psychology of Men & Masculinity (2018) Vol. 20, Iss. 2, pp. 214-225
Closed Access | Times Cited: 32
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
Hannah Rush, Laura Murphy, Alicia K. Morgans, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 8, pp. 825-836
Open Access | Times Cited: 24
Prostate Cancer From a Sex and Gender Perspective: A Review
Martin M. Muermann, Richard J. Wassersug
Sexual Medicine Reviews (2021) Vol. 10, Iss. 1, pp. 142-154
Closed Access | Times Cited: 19
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
Duncan C. Gilbert, Matthew Nankivell, Hannah Rush, et al.
Clinical Oncology (2023) Vol. 36, Iss. 1, pp. e11-e19
Open Access | Times Cited: 7
Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial
Nicholas Russell, Rudolf Hoermann, Ada S. Cheung, et al.
European Journal of Endocrinology (2018) Vol. 178, Iss. 5, pp. 565-576
Open Access | Times Cited: 19
Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform
Duncan C. Gilbert, Trinh Duong, Matthew R. Sydes, et al.
BJU International (2018) Vol. 121, Iss. 5, pp. 680-683
Open Access | Times Cited: 18
Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population‐based cohort of men with intermediate‐ and high‐risk prostate cancer
Wee Loon Ong, Farshad Foroudi, Sue Evans, et al.
BJU International (2017) Vol. 120, Iss. S3, pp. 35-42
Open Access | Times Cited: 17
Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform
Clare Gilson, S. Chowdhury, Mahesh Parmar, et al.
Clinical Oncology (2017) Vol. 29, Iss. 12, pp. 778-786
Open Access | Times Cited: 17
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study
Yvette Zimmerman, Mark Frydenberg, Hendrik Van Poppel, et al.
European Urology Open Science (2022) Vol. 45, pp. 59-67
Open Access | Times Cited: 9
A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials
Matteo Quartagno, Tim P. Morris, Duncan C. Gilbert, et al.
Clinical Trials (2023) Vol. 20, Iss. 6, pp. 594-602
Open Access | Times Cited: 5
Supplemental estrogen and caloric restriction reduce obesity-induced periprostatic white adipose inflammation in mice
Priya Bhardwaj, Takahiro Ikeda, Xi Kathy Zhou, et al.
Carcinogenesis (2019) Vol. 40, Iss. 7, pp. 914-923
Open Access | Times Cited: 14
Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer
Sanjay Kumar, Sanjeev Gurshaney, Yori Adagunodo, et al.
Frontiers in bioscience (2018) Vol. 23, Iss. 11, pp. 1987-2000
Open Access | Times Cited: 13
Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experience
Amarnath Challapalli, Steve Edwards, Paul Abel, et al.
Clinical and Translational Radiation Oncology (2018) Vol. 10, pp. 29-35
Open Access | Times Cited: 11
Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient‐reported outcomes in randomized controlled trials to support clinical decision‐making
Mieke Van Hemelrijck, Francesco Sparano, Lisa Moris, et al.
Cancer Medicine (2020) Vol. 9, Iss. 12, pp. 4039-4058
Open Access | Times Cited: 10
Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial
Nicholas Russell, Rudolf Hoermann, Ada S. Cheung, et al.
European Journal of Endocrinology (2022) Vol. 187, Iss. 5, pp. 617-627
Closed Access | Times Cited: 6
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
Herjan J.T. Coelingh Bennink, Jan Krijgh, Jan F M Egberts, et al.
Endocrine Connections (2022) Vol. 11, Iss. 12
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top